Buscar
Neuronetics Inc
STIMAñadir a la lista de seguimiento
1.410USD
+0.060+4.44%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
98.11MCap. mercado
PérdidaP/E TTM
Más Datos de Neuronetics Inc Compañía
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Información de Neuronetics Inc
Símbolo de cotizaciónSTIM
Nombre de la empresaNeuronetics Inc
Fecha de salida a bolsaJun 28, 2018
Director ejecutivoMr. Keith J. Sullivan
Número de empleados716
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección3222 Phoenixville Pike
CiudadMALVERN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19355
Teléfono18776007555
Sitio Webhttps://neurostar.com/neuronetics/
Símbolo de cotizaciónSTIM
Fecha de salida a bolsaJun 28, 2018
Director ejecutivoMr. Keith J. Sullivan
Ejecutivos de Neuronetics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.06M
+1.46%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
625.02K
+5.80%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
340.45K
+8.81%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
190.35K
+15.76%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
170.89K
+17.56%
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.06M
+1.46%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
625.02K
+5.80%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
340.45K
+8.81%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
190.35K
+15.76%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
170.89K
+17.56%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Neuronetics Inc?
Los cinco principales accionistas de Neuronetics Inc son: Mr. Sasha Cucuz
¿Cuántas instituciones poseen acciones de Neuronetics Inc (STIM)?
A fecha de 2026Q1, 236 instituciones poseen acciones de Neuronetics Inc, con un valor de mercado combinado de aproximadamente 47.87M, lo que representa el 68.80% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -7188276.00.
¿Cuál es la mayor fuente de ganancias de Neuronetics Inc?
El 2026Q1, el segmento empresarial Clinic revenue generó la ganancia más alta para Neuronetics Inc, ascendiendo a 86.98M y representando el 58.31% de la ganancia total.